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The peak signal or the signal at a predetermined, ﬁxed time point after d-luciferin injection may be used for the quantitative
analysis of in vivo bioluminescence imaging. We repeatedly performed sequential bioluminescence imaging after subcutaneous
injection of d-luciferin in mice bearing subcutaneous tumors. The peak time in each measurement became shorter early after
cell inoculation, presumably due to gradual establishment of intratumoral vasculature, and reached a plateau of about 10 min
on day 10. Although the correlation between the signal at a ﬁxed time point and the peak signal was high, the signal at 5 or 10
min normalized for the peak signal was lower for earlier days, which caused overestimation of tumor growth. The time course
of the signals after d-luciferin injection may vary with time after cell inoculation, and this variation should be considered when
determining the imaging protocol for quantitative bioluminescence tumor monitoring.
1.Introduction
In vivo bioluminescence imaging (BLI) allows the evaluation
of the magnitude and distribution of the expression of the
luciferase gene in intact small animals and is widely used
for monitoring tumor model animals [1, 2]. In vivo BLI
is noninvasive and permits the longitudinal assessment of
disease progression and therapeutic eﬀects in a given animal,
which improves the reliability and eﬃciency of experiments.
In addition to its convenience and excellent sensitivity, its
capability for quantitative assessment is a crucial advantage
of in vivo BLI for tumor monitoring [3–6].
In bioluminescence tumor monitoring, mice are usu-
ally inoculated with tumor cells that stably express ﬁreﬂy
luciferase and then are given intravenous, intraperitoneal,
or subcutaneous injections of d-luciferin, the substrate for
ﬁreﬂy luciferase [7, 8]. d-Luciferin, administered intraperi-
toneally or subcutaneously, is absorbed into the blood, is
delivered by the blood ﬂow, enters the tumor cells, and
is oxidized by luciferase, resulting in light emission. The
bioluminescence signal increases gradually, reaches a peak
10–20min after injection, and then decreases gradually. The
peak signal, the signal intensity at the peak, is used as a
quantitative indicator of the luciferase activity and, conse-
quently, of the tumor burden. However, sequential imaging
after d-luciferin injection is required to determine the peak
signal. To improve the throughput of the measurements,
many researchers perform image acquisition at a single,
predetermined time point after d-luciferin injection and use
the signal on the image for quantitative analysis. The peak
time depends on various factors, including the location of
the tumor, injection route, and injection dose [7–9], and
the timing of imaging is determined for each experimental
protocol, based on the peak time estimated in preliminary
experiments. It has been reported that the signal at a
ﬁxed time point and the peak signal similarly represent the
tumor burden [8, 10, 11], justifying the single-point imaging
strategy. However, prolongation of the peak time has been2 International Journal of Biomedical Imaging
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Figure 1: Representative time-intensity curves in a mouse obtained
3, 7, and 14 days after cell inoculation. The signal normalized for
the peak signal of the respective curve was plotted against time after
d-luciferin injection.
shown after the administration of an antivascular agent [12].
Although the peak time has been reported to be independent
of tumor size [10], diﬀerences in the peak time have been
observed on diﬀerent days after cell inoculation in other
studies [13, 14]. Tumor growth and therapeutic intervention
may aﬀect the time course of the bioluminescence signal
afterd-luciferininjection and, consequently,the relationship
between the peak signal and the signal at a ﬁxed time point
in a given tumor.
In this paper, we performed sequential imaging after
d-luciferin injection in mice bearing subcutaneous tumors
and observed tumor growth longitudinally. We selected
subcutaneous injection as the administration route for d-
luciferin because intraperitoneal injection can rarely cause
intrabowel injection, resulting in erroneously weak signal,
whilesubcutaneousinjectionisfreefromtheriskofinjection
failure [8]. The time course of the bioluminescence signal
intensity after d-luciferin injection was evaluated, and the
relationship between the peak signal and the signal at a ﬁxed
time point and its change with days after cell inoculation
were determined. The aim of this paper was to investigate
the eﬀect of imaging timing on the quantitative results of
bioluminescence tumor monitoring.
2.MaterialsandMethods
2.1. Cell Lines. The human colon cancer cell line HCT116
was transfected with the ﬁreﬂy luciferase gene using the
retroviralmethoddescribedpreviously[8,15].Thecellswere
named HCT116-Luc cells and were maintained in McCoy’s
5A medium (Invitrogen, Grand Island, NY) supplemented
with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS)
and 1% penicillin/streptomycin (Invitrogen). Cell cultures
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Figure 2: Peak time plotted against days after cell inoculation. The
error bars indicate the standard errors.
were incubated at 37◦C under 5% CO2. Fireﬂy luciferase
was stably expressed under the control of the long-terminal
repeat of Moloney murine leukemia virus in these cells.
2.2. Animals. Six 8-week-old female BALB/c nu/nu mice
were inoculated subcutaneously in the dorsal ﬂank with 5 ×
105 HCT116-Luc cells mixed with Matrigel (BD Biosciences,
San Jose, CA). The mice were obtained from SLC Japan
(Hamamatsu, Japan) and handled in accordance with the
guidelines of the Institute of Medical Science, University of
Tokyo. The experiments were approved by the committee for
animal research at the institution.
2.3. In Vivo BLI. In vivo BLI was performed using a cooled
charge-coupled device camera system (IVIS Imaging System
100; Xenogen/Caliper Life Sciences, Alameda, CA) 3, 5, 7,
10, 12, 14, 19, 21, 24, and 28 days after the inoculation
of HCT116-Luc cells. Mice were injected with 75mg/kg d-
luciferin (Beetle Luciferin Potassium Salt, Promega, Madi-
son, WI) in 100µL of phosphate-buﬀered saline subcuta-
neously near the scapula and were placed in the light-tight
chamber of the imaging system under isoﬂurane anesthesia.
Beginning 5min after injection, dorsal luminescent images
with an exposure time of 1s were acquired sequentially
at a rate of one image per min until 20min after d-
luciferin injection. Data acquisition was continued until
40min postinjection on days 3 or 5 and until 25min on day
7, because of the prolonged time course of light emission.
Binning was 4 and the ﬁeld of view was 15cm.
2.4. Data Analysis. An elliptical region of interest (ROI)
was placed over the tumor, and the total signal in the
ROI (photons/s) was quantiﬁed using Living Image software
(version 2.50; Xenogen/Caliper Life Sciences). The same ROI
was applied to all images acquired sequentially in a single-
imaging session for a given mouse. The total signal intensityInternational Journal of Biomedical Imaging 3
0
20
40
60
80
100
0
5 10 15 20 25 30
5min
10min
15min
20min
N
o
r
m
a
l
i
s
e
d
s
i
g
n
a
l
(
%
)
Days after cell inoculation
Figure 3: Relationship between days after cell inoculation and the
normalized signal. The signal obtained at a ﬁxed time point after
d-luciferin injection was normalized for the peak signal. The error
bars indicate the standard errors.
was plotted against the time after d-luciferin injection
to generate a time-intensity curve. The peak time was
determined from the time-intensity curve, and the changes
in the peak time with days after tumor cell inoculation were
evaluated. The peak signal was deﬁned from the curve as an
indicator of tumor burden. In addition to the peak signal,
the signals at ﬁxed time points (5, 10, 15, and 20min) after
d-luciferin injection were determined as alternatives to the
peak signal. The signal in a given time-intensity curve was
normalized for the peak signal in the curve to represent
the pattern of temporal changes after d-luciferin injection.
The normalized signal at a ﬁxed time point was assessed
in relation to the number of days after cell inoculation to
evaluatetheusefulnessofthesignalataﬁxedtimepointasan
alternative to the peak signal. The signal was divided by the
signal obtained on day 3 in the respective animal to calculate
thegrowthratioasanindicatoroftumorgrowth.Thegrowth
ratio was plotted against days after cell inoculation and was
compared among values obtained at diﬀerent time points
after d-luciferin injection. In addition, the signal at a ﬁxed
time point was compared to the peak signal in the respective
time-intensity curve, using all curves obtained from the six
m i c eo nv a r i o u sd a y s( n = 60). Linear regression analysis
was performed by the least-squares method after logarithmic
transformation.
3. Results
T h es u b c u t a n e o u st u m o r sw e r ev i s u a l i z e da sb r i g h ta r e a so n
the luminescent images on day 3, and the bioluminescence
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Figure 4: The growth ratio calculated using the signals obtained at
varioustimepointsafterd-luciferininjection.Thegrowthratiosare
plotted on a logarithmic scale. The error bars indicate the standard
errors.
signals intensiﬁed with days after tumor cell inoculation.
The tumor diameter increased from about 5mm on day 7
to about 15mm on day 28. On day 3, the bioluminescence
signal increased slowly after subcutaneous injection of d-
luciferin (Figure 1) reached a peak with a mean peak time of
26.3min (Figure 2), and then decreased. Subsequently, the
initial increase became more rapid and the peak time was
shortened.Onday10orlater,themeanpeaktimewasalmost
constant at around 10min.
On day 3, the signal at 5min was much lower than the
peak signal, consistent with the long peak time (Figure 1).
The mean normalized signal at 5min was 12.9% on day 3
and increased to about 70% on day 10 or later (Figure 3).
The signal at 10min well approximated the peak signal
on day 7 or later, leading to a mean normalized signal
of more than 95%. However, the mean normalized signal
at 10min was only 65.2% and 63.5% on days 3 and 5,
respectively. The signal at 15min was obviously lower than
the peak signal; however, the normalized signal at 15min
did not show a consistent increase or decrease over days.
The normalized signal at 20min was high on days 3–7 and
decreased substantially from day 10 on, due to a signiﬁcant
reduction in the signal after the peak.
The peak signal increased over days after cell inoculation,
consistent with tumor growth, and the mean growth ratio
calculated from the peak signal was 106.9 on day 14 and
294.7onday28(Figure 4).Thegrowthratiowasmuchlarger
usingthesignalat5minthanwhenusingtheotherindicators
of bioluminescence signal intensity. The mean growth ratio
calculated from the signal at 5min was 692.6 on day 14 and4 International Journal of Biomedical Imaging
2302.4onday28.Theoverestimationofthegrowthratiowas
reduced markedly but was still evident using the signal at
10min (165.5 on day 14, and 455.9 on day 28). The temporal
proﬁle of the growth ratio using the signal at 15min was
matched well with that observed using the peak signal. The
growth ratio was underestimated using the signal at 20min.
The signal at a ﬁxed time point after d-luciferin injection
was closely correlated with the peak signal, irrespective of
the time point used for analysis (Figure 5). The correlation
coeﬃcient was higher using the signal at 10 or 15min
than when using the signal at 5 or 20min. As a result
of the underestimation on day 3, weak signals tended
to be underestimated using the signal at 5min, and the
discrepancy between the regression line and the line of
identity was relatively large.
4. Discussion
In this paper, we assessed the time course of the biolumi-
nescence signal after d-luciferin injection in relation to the
number of days after tumor cell inoculation and investigated
the eﬀect of imaging timing on quantitative tumor monitor-
ing using in vivo BLI. The initial increase in the signal after
subcutaneous d-luciferin injection was slow, and the peak
time was long early after tumor cell inoculation. The initial
increasebecamemorerapidandthepeaktimewasshortened
as the number of days after inoculation increased, reaching a
plateau on day 10. The time course of the bioluminescence
signals during each measurement appears to depend mainly
on the rate of absorption of d-luciferin into the blood and
the rate of its delivery to the tumor by the blood ﬂow. Since
the absorption rate is unlikely to diﬀer with days after cell
inoculation, the change in blood supply to the tumor is
likely responsible for the changes in the time course of the
bioluminescence signals. We speculate that the delivery of d-
luciferin to the tumor was slow early after cell inoculation
due to insuﬃcient vascularization, which made the elevation
of intratumoral d-luciferin concentration timeconsuming.
Later, the establishment of the tumor vasculature likely
enhanced the delivery of d-luciferin to the tumor, which
shortened the peak time. In vivo, BLI is highly sensitive
to luciferase-expressing cells and detects them even early
after cell inoculation; however, one should note that the
time course of the signal after d-luciferin injection may be
delayed because the blood supply to the tumor has not been
established early after cell inoculation.
In this paper, we regarded the peak signal as the standard
andevaluatedtheusefulnessofthesignalatapredetermined,
ﬁxed time point after d-luciferin injection as an alternative
to the peak signal. Ideally, the signal at the ﬁxed time point
would be 100% after normalization for the peak signal. If
the normalized signal is substantially less than 100% but
stable over days after cell inoculation, the signal at a ﬁxed
time point will underestimate the peak signal but give the
same tumor growth ratio as the peak signal. The signal
at 5min was much lower than the peak signal, and the
normalized signal at 5min was much lower than 100%,
implying marked underestimation of the peak signal. More
importantly, the normalized signal at 5min varied with days.
It was especially low early after cell inoculation and increased
with days consistent with the shortening of the peak time. As
a result of the predominant underestimation on day 3, the
tumor growth was greatly overestimated using the signal at
5 min as an indicator of tumor burden compared to using
the peak signal. It is noteworthy that the signal at a ﬁxed
time point after d-luciferin injection relative to the peak
signal may change with days after tumor cell inoculation
and that quantitative assessments using diﬀerent imaging
timings may provide diﬀerent estimates of tumor growth. In
our tumor model, the peak time was about 10min, except
during the early period after cell inoculation. When the
single-point imaging strategy is adopted, the signal at 10min
is likely to be used as an indicator of tumor burden. The
normalized signal at 10min was close to 100% on day 7 or
later, but deﬁnitely lower before day 7. Consequently, the
tumor growth was overestimated using the signal at 10min
compared to using the peak signal. The normalized signal
at 15min was deﬁnitely lower than 100%, but did not vary
markedly over days, and thus the discrepancy in the growth
rate between the signal at 15min and the peak signal was
relatively small. The optimal imaging timing to obtain an
alternative to the peak signal may not necessarily correspond
to the peak time determined for a well-established tumor.
The signal at a ﬁxed time point after d-luciferin injection
was closely correlated with the peak signal, irrespective of
the time point used for analysis, apparently justifying the
single-point imaging strategy. However, the signal at 5min
tended to be lower than the peak signal at low signal levels,
which was attributable to the predominant discrepancy early
after cell inoculation. A possible systematic discrepancy
between the signal at a ﬁxed time point and the peak signal
should be considered, despite the high correlation between
them. A high correlation does not necessarily guarantee
exchangeability.
Since the time course of bioluminescence after d-
luciferin injection changes with days after tumor cell inoc-
ulation and since the changes aﬀect the observations of the
tumor growth, sequential imaging for each measurement
appears to be desirable. If the single-point imaging strategy
is adopted to improve the throughput of the measurements,
thepossibleeﬀectofthechangesinpeaktimeonquantitative
analysis should be considered. We recommend evaluating
the relationship between the time course of signals after d-
luciferin injection and the number of days after cell inocu-
lation in preliminary experiments using a small number of
animals.
The signal early after d-luciferin injection appears to
be greatly aﬀected by tumor blood ﬂow. The peak signal is
obtained at a time point when the delivery of d-luciferin is
attained suﬃciently, and it presumably reﬂects the luciferase
activity relatively faithfully. The ratio of the signal at an
early time point to the peak signal may serve as an indicator
of tumor blood ﬂow. Dynamic contrast-enhanced magnetic
resonance imaging (MRI) allows the assessment of tumor
blood ﬂow; however, the assessment requires an MRI system,
which is much more expensive than a system for BLI.
In addition, because of the limited sensitivity to contrastInternational Journal of Biomedical Imaging 5
106 107 108 109 1010 1011
106
107
108
109
1010
1011
S
i
g
n
a
l
a
t
5
m
i
n
(
p
/
s
)
Peak signal (p/s)
R2 = 0.977
y = 1.27x −2.806
(a)
y = 1.075x −0.754
R2 = 0.995
106 107 108 109 1010 1011
106
107
108
109
1010
1011
Peak signal (p/s)
S
i
g
n
a
l
a
t
1
0
m
i
n
(
p
/
s
)
(b)
106
107
108
109
1010
1011
106 107 108 109 1010 1011
S
i
g
n
a
l
a
t
1
5
m
i
n
(
p
/
s
)
Peak signal (p/s)
y = 0.99x −0.02
R2 = 0.993
(c)
106
107
108
109
1010
1011
106 107 108 109 1010 1011
S
i
g
n
a
l
a
t
2
0
m
i
n
(
p
/
s
)
Peak signal (p/s)
y = 0.891x +0.811
R2 = 0.984
(d)
Figure 5: Correlation of the signals at various time points after d-luciferin injection with the peak signal. The signals are presented on
a logarithmic scale. The solid and broken lines represent the regression line and the line of identity, respectively. Linear regression was
performed after logarithmic transformation.
materials, evaluating blood supply to small tumors by using
dynamic contrast-enhanced MRI is diﬃcult. The excellent
sensitivity of BLI may be especially useful for assessing
blood ﬂow in small tumors. The delayed peak and the low
normalized signal at 5min observed in this study appear to
imply insuﬃcient vascularization of the tumor early after
cell inoculation. Such prematurity may aﬀect not only the
quantitative analysis of in vivo BLI, but also the phenotype
and therapeutic response of the tumor. One may use tumors
for experiments after the tumors and their vasculature are
established, and the peak time and normalized signal at
5min reach plateaus. The evaluation of blood supply using
sequential BLI may aid in characterizing tumor models.
In summary, the time course of bioluminescence sig-
nals after d-luciferin injection varies over days after cell
inoculation in mice bearing subcutaneous tumors, and
such variation should be considered when determining the
imaging protocol and the method of quantitative analysis.
Although the signal at a predetermined, ﬁxed time point
after d-luciferin injection is correlated with the peak signal,6 International Journal of Biomedical Imaging
thetimepointusedforanalysisaﬀectsthecorrelationandthe
e s t i m a t e so ft u m o rg r o w t h .T h et i m ec o u r s ea f t e rd-luciferin
injection may provide an indicator of tumor blood ﬂow and
contribute to the assessment of tumor model animals.
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